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Abstract
Purpose: The role of the minimal residual disease (MRD) in follicular lymphoma is still debated. In this
study, we assessed whether the BCL2/IGH rearrangement could have a prognostic role in patients receiving
R-CHOP, R-FM, or R-CVP.
Experimental Design: DNAs from 415 patients among the 504 cases enrolled in the FOLL05 trial
(NCT00774826) were centralized and assessed for the BCL2/IGH at diagnosis, at the end of treatment, and
after 12 and 24 months.
Results: At diagnosis, the molecular marker was detected in 53% of cases. Patients without molecular
marker or with a lowmolecular tumor burden (<1 104 copies) showed higher complete remission (CR)
rate and longer progression-free survival (PFS; 3-year PFS 80% vs. 59%; P ¼ 0.015). PFS was significantly
conditioned by the PCR status at 12 and 24months, with 3-year PFS of 66% forMRD cases versus 41% for
thoseMRDþ at 12months (P¼ 0.015), and 84% versus 50% at 24months (P¼ 0.014). TheMRDnegativity
at 12 and 24months resulted in an improved PFS both in CR and in partial remission (PR) patients (3-year
PFS¼ 72% for cases CR/PCR vs. 32% for those CR/PCRþ vs. 62% for those PR/PCR and 25% for patients
in PR/PCRþ; P¼ 0.001). The prognostic value ofMRDat 12 and24months of follow-upwas confirmed also
in multivariate analysis.
Conclusions: In this study, standardized molecular techniques have been adopted and applied on
bone marrow samples from a large cohort. Data reported show that the MRD detection is a powerful
independent predictor of PFS in patients with follicular lymphoma receiving conventional chemo-
immunotherapy. Clin Cancer Res; 20(24); 6398–405. 2014 AACR.
Introduction
The monitoring of minimal residual disease (MRD)
in follicular lymphoma is a well-established predictor
of outcome in the autologous transplantation scenario,
in which the negative impact on survival of patients
receiving BCL2/IGHþ autologous stem cells and of the
MRD persistence after transplantation have been already
demonstrated (1–3). On the contrary, the role of MRD
after conventional treatments is still debated (4, 5). The
first critical point is what is the best technique for MRD
assessment; indeed, more than half of patients affected by
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follicular lymphoma carry the t(14;18)(q32;q21) and the
correspondent fusion gene BCL2/IGH that could be easily
detectable by the PCR (6). Usually, the breakpoint is
inside the major breakpoint region (MBR; ref. 7), whereas
most of the remaining cases show the rupture in other
regions, namely the minor cluster region (mcr), and the
30MBR (8). Breakpoints occurring in the MBR can be used
for MRD purposes using standardized qualitative and
quantitative PCR reactions (9), whereas PCR-based assays
for translocations occurring at other breakpoints have not
been yet extensively validated (10). In the remaining
cases, patient-specific rearrangement of the immunoglo-
bulins heavy chains (IGH) could be also detected, but this
method is expensive, time-consuming, and offers a lower
sensitivity (11).
The second issue concerns the best timing for the MRD
assessment. In particular, it is unclear whether MRD would
play any predictive role already at the end of treatment, or if
its significance would be higher during the follow-up,
before or after autotransplantation, or during the rituximab
maintenance.
The introduction of rituximab (R) in the clinical practice
and the possibility of consolidation with 90Y-ibritumomab
significantly increased the probability of achieving theMRD
eradication (12, 13).
van Oers and colleagues (14) showed that the BCL2/
IGH–positive status before treatment with R-CHOP in
relapsed/resistant patients did negatively condition the
progression-free survival (PFS). In another study conducted
by the Italian Lymphoma Group, MRD resulted as a
powerful outcome predictor in patients receiving rituximab
maintenance (15).
Moreover, after the introduction of the qPCR during the
last decade, the role of the "molecular tumor burden" has
been also evaluated: Rambaldi and colleagues (16) reported
that 70% of patients with low amount of BCL2/IGH copies
achieved complete remission (CR) compared with only
26% of those with higher BCL2/IGH levels, with a signifi-
cant advantage on the event-free survival.
Thus, in the 2005 the Fondazione Italiana Linfomi
(FIL) decided to assess the MRD in patients with follicu-
lar lymphoma enrolled in the large phase III multicenter
study FOLL05 (NCT00774826). In this trial, conduct-
ed between March 2006 and September 2010, 534
untreated patients affected by advanced follicular lym-
phoma were randomized to receive R-CHOP (that
resulted to be the best regimen), R-CVP, or R-FM, as
previously reported (17).
Here, we present the results of the molecular assessment
of patients enrolled in the FOLL05 trial providing new
insights on some still open issues about MRD in patients
with follicular lymphoma receiving chemoimmunotherapy.
Patients and Methods
Study design and treatment
The prospective, randomized, multicenter phase III trial
FOLL05 (NCT00774826) was conducted in 58 Italian cen-
ters, in accordance to the Declaration of Helsinki. The
clinical trial included previously untreated patients, aged
18 to 75 years, with a histologic confirmed diagnosis of
follicular lymphoma grade 1, 2, and 3a, Ann Arbor stages II
to IV, ECOG (Eastern Cooperative Oncology Group) per-
formance status 0 to 2, and active disease (18). In addition
to the physical examination and total body CT scan, before
enrollment all patients underwent bone marrow (BM)
biopsy and aspirate for assessment of the BCL2/IGH fusion
gene. Central pathology review was performed for all grade
3 follicular lymphomas or when the local pathologist did
not specify grading. In each center all BM biopsies were
assessed by immunohistochemistry (at least CD20, CD10,
and CD5), to confirm the morphologic diagnosis of
follicular lymphoma. All patients underwent an interme-
diate CT scan for assessment of response after cycle 3 and at
treatment completion. Clinical response assessment was
performed with physical examination, laboratory tests, and
total body CT scan; BM biopsy and aspirate were required
only for patients with initial BM involvement or BCL2/IGH
positivity. Quality of response was defined according to the
standardized international criteria (19). The conversion of
the MRD negativity to the MRD positivity was not consid-
ered as relapse in the computation of PFS.
Molecular assays
Qualitative BCL2/IGH rearrangement analysis was
planned at baseline, at 6 weeks after the end of treatment,
and then every 6months during the second and third year of
Translational Relevance
Follicular lymphoma represents an indolent lympho-
proliferative disease, but the incidence of relapse still
interests more than one third of the responsive patients.
Thus, the introduction of the rituximab maintenance
and the monitoring of the minimal residual disease
(MRD) could be useful for starting a preemptive therapy
and delaying the clinical relapse. In this study, we
assessed 415 patients affected by follicular lymphoma
receiving R-CHOP, R-FM, or R-CVP by qualitative and
quantitative PCR for BCL2/IGH rearrangement. We
showed that: (i) thepresence of theBCL2/IGH rearrange-
ment in the bone marrow (BM) at diagnosis has got a
predictive value on progression-free survival (PFS); (ii) a
low molecular tumor burden at diagnosis positively
impacts on the quality of response and PFS; (iii) the
MRD negativity after 12 and 24 months off treatment
correlates with a better outcome; (iv) R-CVP is the
regimen offering a lower molecular disease clearance in
comparison with R-CHOP and R-FM. Thus, a molecular
assessment during thework-upof patientswith follicular
lymphoma could be considered as a sort of "dynamic"
risk score that could lead to treat by rituximab patients
losing the MRD negativity or to avoid maintenance in
patients at very low risk of relapse.
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follow-up. All qualitative molecular analyses were central-
ized at the molecular laboratory of the Division of Hema-
tology of the Pisa University (Italy). The four laboratories
composing the FIL–MRD network retrospectively per-
formed qPCR assays at diagnosis and at the end of therapy,
after the inter-laboratory standardization of the used
techniques.
DNA was extracted from BM mononuclear cells by the
Wizard Genomic DNA Purification Kit (Promega). To
amplify BCL2/IGH rearrangement, nested PCR reactions
were performed as previously described (20).
The sensitivity of the qualitative PCR assays was con-
firmed by testing serial dilutions of DNA derived from the
BCL2/IGH–positive DOHH-2 cell line, achieving a limiting
dilution of 1:105. A second reaction for mcr breakpoint
was also performed, as reported in literature (21).
qPCR was performed using the technique previously
described by Ladetto and colleagues (22). Also in this case,
standard curves were constructed usingDNA extracted from
the DOHH-2 cells. Even in this case, the sensitivity was
1:105.
To confirm the specificity of BCL2/IGH rearrangement,
four-paired samples (at diagnosis and after treatment) were
sequenced using the ABI Prism BigDye Terminator Cycle
Sequencing Kit 1.1 and the ABI Prism 3100 Genetic Ana-
lyzer (PE Applied Biosystems).
Statistical analysis
All statistical analyses were performed using the SPSS
17.0 software (SPSS Inc.) at the FIL data center in Modena
(Italy). Because about half of patients with follicular lym-
phoma relapse by the third year after treatment, and overall
survival analyses are not possible in the time frame of the
trial, PFS was chosen as the best surrogate of the efficacy of
treatment. PFS was measured from the date of the study
entry to the last follow-up, or to one of the following events:
death from any cause, disease progression, and relapse.
Survival curves were calculated using the Kaplan–Meier
method, and statistical comparisons between curves were
made using the log-rank test. Post-hoc comparisons were
obtained using the Cox proportional hazard regression
method. The c2 test, Fisher exact test, and Kruskal–Wallis
test were used to compare variables when appropriate. For
establishing the value of quantitative BCL2/IGH rearrange-
ment on relapse, a ROC curve was performed. All statistical
comparisons were two-sided. The date of the last molecular
follow-up was December 30, 2012.
Results
Qualitative PCR positivity before therapy predicts the
clinical response
Five hundred and thirty-four patients were enrolled
into the FOLL05 trial by 58 Italian institutions; 30 pati-
ents were subsequently excluded, and the remaining 504
patients were analyzed. DNAs from 89 cases were not
centralized in Pisa. Consequently, at baseline, 415 of the
504 eligible patients (82%) were assessed for BCL2/IGH
rearrangement by qualitative PCR (see Supplementary
Fig. S1): In 220 cases (53%) the molecular marker was
found. The breakpoint was in the MBR in the 92% of cases
and in the mcr in the remaining 8%. Overall, 227 patients
were scored as showing BM infiltration after the local
microscopy observation; in 40 of them (17.6%), we were
not able to find the BCL2/IGH, probably for the presence
of a rearrangement involving other rare breakpoints.
On the other hand, in 127 of the 188 cases without BM
infiltration at the microscopy (67.5%) the molecular
marker was found, possibly due to a submicroscopic BM
involvement.
Cytogenetic data about translocation between chromo-
some 14 and 18 were not available for this trial.
No significant differences were observed for the main
clinical and prognostic features, and for treatment alloca-
tion, between cases with and withoutmolecular assessment
at enrollment, and between patients resulting PCR or
PCRþ (Tables 1 and 2).
Both PCR positivity and BM infiltration at the enroll-
ment had a significant impact on the quality of response.
The percentage of cases not achieving the complete
response at the end of therapy was higher for patients
PCRþ or BMþ in respect of cases without molecular marker
or BM infiltration [61.9% for PCRþ vs. 38.1% for PCR
patients (P¼ 0.027); 32% for BMþ vs. 21.8% for BM cases
(P ¼ 0.021)].
The 3-year PFS was significantly advantageous for
patients BM/PCR versus those BMþ/PCRþ (74% vs.
55%; P ¼ 0.04).
Molecular tumor burden before therapy significantly
predicts both quality of response and PFS
At the study enrollment, the molecular tumor burden
was assessed by qPCR in 105 cases of the 203 already
positive for MBR breakpoint; this difference between
cases assessed by qualitative and quantitative PCR was
due to the residual availability of DNA. No significant
differences were observed for clinical features and treat-
ment allocation between cases with or without qPCR
assessment (Table 3). The quantization of molecular
tumor burden showed wide interpatients variability: the
median value was 3 103 copies, ranging from 2 105
to 6 copies. The BCL2/IGH copy number did not correlate
with stage, performance status, age (< or >65 year), or
gender, but was significantly higher in patients presenting
with high FLIPI and FLIPI2 score.
When a ROC analysis-computing BCL2/IGH copies (as
continuous variable) versus relapse (as dichotomic vari-
able) was performed, a BCL2/IGH copy number >1 104
was the most predictive value conditioning the quality of
response and the relapse rate. Indeed, among patients with
high molecular tumor burden, overall response rate (ORR)
was significantly lower than in cases with low molecular
tumor burden (38.9% vs. 76.6%; P ¼ 0.006).
Moreover, only 22% of cases showing <1  104 copies
relapsed versus 78% of patients with >1 104 copies (P¼
0.033). The treatment allocation was not different between
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Clin Cancer Res; 20(24) December 15, 2014 Clinical Cancer Research6400
the two cohorts; moreover, cases displaying values <1 
104 showed a clear advantage also in terms of PFS (3-year
PFS 80% vs. 59% for cases with higher molecular tumor
burden; P ¼ 0.015; Fig. 1).
In the multivariate analysis, the molecular tumor burden
significance was analyzed together with FLIPI, BM involve-
ment, quality of response [CR vs. partial remission (PR)
or stable disease], andarmof therapy (R-CVPvs. R-CHOPor
R-FM) A high FLIPI score, missing the CR, and a high
molecular tumor burden before therapy retained their
negative impact on PFS [HR, 2.51; 95% confidence interval
(CI), 2.44–4.3; P ¼ 0.009, 0.010, 0.027, respectively; see
Supplementary Table S1].
In particular, when the molecular tumor burden at diag-
nosis was analyzed in respect of the arm of randomization,
the Mantel–Heanzel analysis confirmed that the high
molecular tumor burden retained its negative impact on
PFS independently from the arm of randomization (HR,
4.97; test for unequal HR: P ¼ 0.929).
The impact of treatment on MRD
At the first time point of molecular observation (6 weeks
after the end of therapy), 3 patients dropped out from the
protocol and 63 samples were not sent to the referral
molecular laboratory; thus, 154 of the 220 previously
PCRþ cases were reassessed by qualitative PCR: 109
(70.8%) achieved the PCR negativity.
To verify the identity of the molecular marker at the end
of treatment with that observed at diagnosis, 4 patients
(8 paired samples) were longitudinally sequenced: all tests
confirmed the specificity of the BCL2/IGH rearrangement.
The MRD status at the end of therapy did not signifi-
cantly correlate with the clinical features, quality of
Table 1. Comparison of patients'
characteristics between cases assessed or not
by qualitative PCR forBCL2/IGH rearrangement
Patients
Qualitative PCR
Characteristics Performed
Not
performed P
Number of patients 415 106
Median age, y 69 68 N.S.
Sex
Male 47% 54% N.S.
Female 53% 46%
Histotype
Grade 1 25% 35%
Grade 2 49% 44% N.S.
Grade 3a 15% 13%
Unclassiﬁed 11% 8%
Ann Arbor stage
II 8% 9%
III 28% 29% N.S.
IV 64% 62%
ECOG performance status
>1 2.7% 2.8% N.S.
FLIPI
0–2 58% 64% N.S.
3–5 42% 36%
FLIPI 2
0–2 64% 75% N.S.
3–5 36% 25%
b2-microglobulin
>UNL 46% 44% N.S.
BM involvement 57% 54% N.S.
Treatment allocation
R-CVP 37% 32%
R-FM 39% 35% N.S.
R-CHOP 32% 33%
Abbreviation: N.S., "statistically not signiﬁcant."
Table 2. Comparison of patients'
characteristics between cases with or without
molecular marker at diagnosis
Patients
Qualitative PCR
Characteristics Positive Negative P
Number of patients 220 195
Median age, y 69 68 N.S.
Sex
Male 52% 55% N.S.
Female 48% 45%
Histotype
Grade 1 39% 31%
Grade 2 44% 43% N.S.
Grade 3a 11% 16%
Unclassiﬁed 6% 10%
Ann Arbor stage
II 6% 12%
III 28% 30% N.S.
IV 66% 58%
ECOG performance status
>1 3.0% 2.7% N.S.
FLIPI
0–2 56% 45% N.S.
3–5 44% 55%
FLIPI 2
0–2 60% 70% N.S.
3–5 40% 30%
b2-microglobulin
>UNL 46% 54% N.S.
BM involvement 45% 55% N.S.
Treatment allocation
R-CVP 33% 33%
R-FM 35% 34% N.S.
R-CHOP 32% 33%
Abbreviation: N.S., "statistically not signiﬁcant."
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response, or therapeutic arm: the percentage of cases
initially PCRþ that became MRD after treatment was
superimposable for patients receiving R-CHOP and R-FM
(39% and 36%, respectively). Interestingly, only 25%
of patients receiving R-CVP achieved the PCR negativity;
even if statistically not significant (P ¼ 0.26), this is
in accordance to that already observed in the clinical
trial, in which R-CVP resulted the arm with higher rate
of events.
Concerning the impact of treatment on the BCL2/IGH
molecular tumor burden assessed in 66 of previously
PCRþ cases, the mean observed reduction was about two
logarithms; a lower molecular tumor burden reduction
was measured in patients receiving R-CVP versus the
remaining ones (decrease >3 log ¼ 21.1% for R-CVP vs.
36.8% for R-FM and 42.1% for R-CHOP, P ¼ 0.07).
The conversion to MRD negativity just after treatment
correlated with a lower probability of relapse and longer
PFS, but it did not reach a statistical significance (relapse
rate, 33%vs. 41%; P¼ 0.363; 3-year PFS 64.3%vs. 53.1; P¼
0.08).
MRD negativity during follow-up has significant
impact on PFS and retains its prognostic significance
also in patients achieving partial response
At the molecular assessment performed after 12 months
from the end of treatment, 63 cases wereMRD, whereas 24
were still MRDþ; after 24 months, 46 cases became MRD,
whereas 19 retained their MRD positivity. The allocation of
patients in the three arms of therapy was not different
between MRDþ and MRD cases.
PFS was significantly conditioned by the PCR status at 12
and 24 months, with 3-year PFS of 66% for PCR cases
Table 3. Comparison of patients'
characteristics between cases with or without
qPCR assessment
Patients
qPCR
Characteristics Assessed
Not
assessed P
Number of patients 105 115
Median age, y 68 67 N.S.
Sex
Male 48% 52% N.S.
Female 46% 44%
Histotype
Grade 1 53% 47%
Grade 2 44% 56% N.S.
Grade 3a 46% 54%
Unclassiﬁed 33% 67%
Ann Arbor stage
II 50% 50%
III 51% 49% N.S.
IV 45% 55%
ECOG performance status
>1 3.8% 1.7% N.S.
FLIPI
0–2 54% 46% N.S.
3–5 58% 42%
FLIPI 2
0–2 56% 44% N.S.
3–5 58% 42%
b2-microglobulin
>UNL 58% 42% N.S.
BM involvement 56% 44% N.S.
Treatment allocation
R-CVP 43% 57%
R-FM 48% 52% N.S.
R-CHOP 50% 50%
N.S. means "statistically not signiﬁcant"
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Figure 1. PFS from the randomization is signiﬁcantly longer in patients
withBCL2/IGH levels <1104 before treatment (continuous dotted line;
P ¼ 0.015).
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Figure 2. PFS from the randomization is signiﬁcantly longer in patients
without BCL2/IGH detectable after 12 months of follow-up (continuous
dotted line; P ¼ 0.015).
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versus 41% for those PCRþ at 12months (P¼ 0.015; Fig. 2),
and 84% versus 50% at 24 months (P ¼ 0.014).
TheMRDnegativity at 12 and 24months from the end of
treatment resulted in an improved PFS both inCR and in PR
patients (3-year PFS ¼ 72% for cases CR/PCR vs. 32% for
those CR/PCRþ vs. 62% for those PR/PCR and 25% for
patients in PR/PCRþ; P ¼ 0.001; Fig. 3).
When the analysis was restricted to the cohort of patients
who achieved CR but then relapsed, the MRD negativity at
12 and 24 months still retained its favorable prognostic
significance [3-year PFS¼ 88% for MRD cases vs. 52% for
those still MRDþ at 12 months (P ¼ 0.046), and 91% vs.
52% at 24 months (P ¼ 0.034)].
When PCR negativity at 12 and 24 months was consid-
ered in multivariate analysis together with FLIPI, BM
involvement, quality of response (CR vs. PR) or stable
disease, and arm of therapy (R-CVP vs. R-CHOP or R-FM),
only the BM involvement at 12 months retained its poor
prognostic role in addition to the MRD persistence (BMþ:
HR, 3.23; 12monthsMRD:HR, 0.38;P¼0.010 and0.016,
respectively; see Supplementary Table S2). At 24 months,
only the persistence of the BCL2/IGH rearrangement con-
ditioned the long-term outcome (24 months MRD: HR,
0.26; 95% CI, 0.07–0.92; P ¼ 0.036; see Supplementary
Table S3).
Moreover, when the prognostic role of the MRD at 12
and 24 months was analyzed in respect of the arm of
therapy, the Mantel–Heanzel test confirmed that the
MRD negativity was a good prognostic factor, indepen-
dently from the type of treatment (HR, 0.44; test for
unequal HR: P ¼ 0.604).
Finally, from the 26 cases still MRDþ after treatment, 13
(50%) achieved the MRD negativity during follow-up; on
the other hand, 21 of the 45 cases MRD after induction
(46%)presented at least onepositive PCRduring follow-up.
There was a good trend to a higher percentage of patients
relapse free at 36months in the cohort of theMRDþ/ cases
(76%) versus cases MRD/þ (46%) versus patients always
MRDþ (21%); P ¼ 0.08.
When 10 cases with both molecular and clinical re-
lapse were evaluated, in 9 of them the molecular relapse
preceded the clinical one for a median of 5 months
(range, 2–8).
Discussion
The results of this large, prospective, and randomized trial
support the usefulness of the MRD evaluation in patients
with follicular lymphoma treated with conventional che-
moimmunotherapy. Four main findings arose from this
study: (i) the presence of the BCL2/IGH rearrangement in
the BM at diagnosis has got a predictive value on PFS;
(ii) a low molecular tumor burden at diagnosis positively
impacts on the quality of response and PFS; (iii) the MRD
negativity after 12 and 24 months off treatment correlates
with a better outcome; (iv) R-CVP is the regimen offering a
lower molecular disease clearance in comparison with
R-CHOP and R-FM.
It is relevant that our study compares favorably with
other reports because of its larger number of patients:
indeed, the majority of reports included not more than
100 cases (12–14). Our study analyzed 415 cases before
treatment (105 by qPCR), and 207 during the further
24 months of follow-up, for overall 1,100 PCR reactions.
Another relevant item is represented by the study design:
although other studies put together results coming from
both peripheral blood and BM, often regardless of the
presence of the molecular marker at diagnosis (14), in our
study only patients PCRþ at diagnosis (always assessed on
BM) were considered for the statistical analysis. This could
be relevant, because differences higher than 1 log have been
reported in favor of BM samples (23). Moreover, qPCR
assays were conducted according to the European EURO-
MRD guidelines (24).
BCL2/IGH rearrangement was detected at diagnosis in
53% of our patients; this percentage could be considered
too low for a marker with prognostic implications; never-
theless, it is worth to consider that in the next future the
availability of primers and probes for detecting the rare
BCL2/IGH breakpoints will increase the number of follic-
ular lymphoma cases with amolecular marker at diagnosis.
Moreover, the percentage of cases with a molecular marker
is superimposable to that previously reported by other
authors (48%–54%; refs. (14, 15, 22).
Obviously, we have to consider that the BCL2/IGH rear-
rangement was detected in 2% to 23% of healthy donors
(25, 26). In our study, all data come from the BM analysis
only and the specificity of rearrangement was confirmed
also by DNA sequencing.
About the clinical impact of the qualitative PCR at diag-
nosis, 61.9% of PCRþ did not reach CR versus 38.1% of
the PCR cases.
As second item, we demonstrated that qPCR, already at
diagnosis, is able to predict the outcome of patients with
follicular lymphoma. Some authors reported that levels of
PF
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PR/MRD−
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Figure 3. PFS from the randomization is signiﬁcantly longer in patients
withoutBCL2/IGH rearrangement during follow-up, independently of the
quality of response; P ¼ 0.001.
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BCL2/IGH <1  103 did not improve quality of response
(14), whereas others showed that cases with low molecular
tumor burden at diagnosis achieved CR more frequently
than those with high molecular tumor burden (15). In our
study, we demonstrated that cases displaying values <1 
104 showed a clear advantage in terms of PFS (3-year PFS
80%vs. 59% for cases with highermolecular tumor burden;
P ¼ 0.015) and ORR (76.6% vs. 38.9%; P ¼ 0.006).
Moreover, we reported that the disappearance of the
molecular marker after therapy positively conditioned the
outcome, with a statistical significance in the long-term
follow-up. The lower significance of the molecular marker
disappearance at the end of treatment could be justified by
the short interval between the last cycle of rituximab and the
MRD assessment; indeed, the long-lasting activity of the
anti-CD20 antibody could underestimate the MRDþ cases.
Interestingly, our data sustain the role of the MRD
negativity not only in patients reaching CR, but also in
those with partial response: 3-year PFS was 62% for
patients in PR and MRD versus 32% for patients in CR
but still MRDþ after 12 months of follow-up. This is
interesting, because it seems to be a real proof of the
importance of the MRD in follicular lymphoma. More-
over, our data are comparable with those reported by the
Nordic Group in mantle cell lymphoma and by our group
in follicular lymphoma, in which MRD was highly pre-
dictive for prolonged response duration also in cases
achieving PR (27, 28).
The fourth finding of this study is that patients treated
with R-CVP had an inferior clearance of the molecular
disease; these data are in perfect accordance with those
from the clinical trial in which PFS and time-to-treat-
ment-failure were shorter for the R-CVP arm (17).
In conclusion, our study sustains the importance of the
BCL2/IGH detection at diagnosis and the utility of theMRD
monitoring during the follow-up of patients with follicular
lymphoma.
All of us agree that FLIPI and FLIPI2 are very good
prognostic factors in follicular lymphoma (29, 30); never-
theless, amolecular assessment during the work-up of these
kind of patients could be considered such as a sort of
"dynamic" risk score that could lead to treat by rituximab
patients losing MRD negativity or to avoid maintenance in
patients at very low risk of relapse.
PET scan is another tool that proved to be highly predic-
tive for outcome in follicular lymphoma. In our study, we
had a small subset of patients inwhichboth toolswere used.
This panel of patients is too small to be conclusive, but we
noticed that PCR was able to discriminate two prognostic
subgroups among PET cases, with MRD negativity asso-
ciated with longer PFS (Luminari S; unpublished data).
Moreover, we could speculate that the predictive value of
MRD could be jeopardized by the use of rituximab main-
tenance that is now the standard of care in follicular lym-
phoma. However, a recent study from our group in old
patients receiving R-FND followed by a brief consolidation
with rituximab and a random between rituximab mainte-
nance or observation showed power thatMRD still retained
an excellent prognostic discrimination among patients
receiving rituximab maintenance (15). Moreover, our data
suggest that a preemptive strategy similar to that used by the
Nordic group in mantle cell lymphoma might appear of
interest for future studies in follicular lymphoma, as also
shown by the retrospective experience from our group (28).
In this line, the FIL recently started a new large random-
ized phase III trial based on the MRD and PET status assess-
ment after R-CHOP induction (FOLL12-EUDRACT NUM-
BER: 2012-003170-60, Clinical trial.gov NCT00774826).
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